Skip to content

PulmoGate Raises ¥330M to Bridge ILD Specialist Gaps—AI Waits, Human Networks Move First

·StartupReader editorial desk· 1 min readReviewed by our editors
FUNDING. ¥330M raised by PulmoGate, ILD specialist network. Nagoya University.

PulmoGate, a startup founded at Nagoya University, has secured approximately ¥330 million in seed funding, but its focus isn’t on AI-driven diagnostics. Instead, the company is developing an online platform for "expert meetings" (MDD) that connects pulmonologists, radiologists, and pathologists to discuss interstitial lung disease (ILD) cases—conditions where specialist shortages delay or prevent proper care. The approach reflects a pragmatic recognition: regulatory hurdles and clinical validation for medical AI are lengthy, so the company is prioritizing a human-centered system that can deliver immediate value.

The funding round, which includes participation from Teijin Pharma, highlights a broader debate in healthtech: whether AI should first prove its worth by enhancing human collaboration or leap directly into autonomous decision-making. PulmoGate’s choice to start with a digital MDD network—adapted from Nagoya University’s PROMISE study—suggests that the market may be more receptive to solutions that fill gaps today rather than waiting for AI to mature.

Sources: note.com

“This funding round signals a deliberate shift in medical AI development: instead of rushing to deploy autonomous diagnostics, PulmoGate is first building a **human-led collaboration network** to address critical gaps in rare-disease care—a strategy that may set a new standard for how deeptech startups approach product sequencing.”
— StartupReader
ShareLinkedInXWhatsApp

One of the funding rounds reported in the week of 16–22 November 2026. See every round that week.

Read the original reporting

The outlets below did the original reporting.

Related briefs

This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.